echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Rheumatology: elevated serum CA72-4 predicts gout attacks at the start of urate-lowering therapy, a prospective cohort study

    Rheumatology: elevated serum CA72-4 predicts gout attacks at the start of urate-lowering therapy, a prospective cohort study

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Purpose: Gout attacks are common at the start of urate-lowering therapy (ULT), but the predictors of these episodes are unclear
    The aim of the study was to determine whether serum CA72-4 is an independent predictor of gout attacks during ULT initiation.

    Methods: A prospective cohort study
    was conducted between March 2021 and January 2022.
    Male patients with gout who had at least one gout attack in the past year and at least three serum CA72-4 measurements
    in the past six months were included.
    Participants were grouped
    according to their highest recorded serum CA72-4 level (above or within the normal range).

    All participants took febuxostat 20 mg daily without seizure prophylaxis and had face-to-face visits every four weeks until 24 weeks
    The incidence
    of gout attacks was compared between the two groups.
    Inverse stepwise logistic regression analysis is used to determine risk factors
    associated with episodes.
    ROC curve analysis is used to evaluate the prediction effect

    Results: A total of 193 people completed the study (79 with high CA72-4; 114 people with normal CA72-4).

    The cumulative incidence of at least one gout attack was 48.
    1% (62.
    1% in the high CA72-4 group, 38.
    4% in normal CA72-4, P = 0.
    001), and the recurrence (≥ 2) gout attack rate was 33.
    0% (47.
    1% in the high CA72-4 group, 23.
    2% in normal CA72-4, P <0.

    High CA72-4, duration of disease, intra-articular gout size, glucose, high-density lipoprotein cholesterol, and erythrocyte sedimentation rate are independent risk factors
    for gout attacks.
    Serum CA72-4 alone predicted recurrent episodes, with an AUC of 0.
    63 (95% CI = 0.
    54 to 0.
    71) and an AUC of 0.
    78 (95% CI = 0.
    71 to 0.
    when combined with other independent variables.

    Conclusion: High serum CA72-4 predicts the risk of gout attacks during ULT initiation.



    Hu S, Sun M, Li M, et al.
    Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study [published online ahead of print, 2022 Nov 21].
    Rheumatology (Oxford).
    2022; keac656.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.